Abstract: A computer-implemented method for material cyber event modeling includes: generating a cyber event catalog based on a past cyber event, the catalog including a plurality of cyber events, wherein generating catalog further includes: determining a distribution of all event parameters by extrapolating data from a past event; and assigning a set of restriction rules, wherein the parameter distribution and the set of restriction rules are used to create events in the catalog; simulating a cyber event, of the plurality of events in the catalog, to predict whether an organization is affected by a simulated cyber event, wherein the organization is an organization selected from a hazard table, and wherein the simulating cyber event simulates malicious activity; and estimating a damage of the cyber event on the organization by employing a damage function, including generating an exceedance probability (EP) curve for the cyber event, for at least one materiality category.

Abstract: Systems and methods are disclosed for providing a cyber resilience rating. A method can include obtaining a plurality of entity indicators. The method can include determining a peer group of entities for the entity based on the entity indicators. The method can include obtaining a plurality of loss event records for the peer group. The method can include executing, based on the loss event records, a plurality of Monte Carlo simulations to generate loss simulation data. The method can include identifying, based on the loss simulation data, an expected probability value. The method can include providing a risk factor score indicative of a cyber security risk of the entity based on the identified expected probability value. The method can include providing a cyber resilience rating for the entity based on a combination of the risk factor score, a fortitude factor score, and a governance factor score.

Abstract: Systems and methods are disclosed for providing a cyber resilience rating. A method can include obtaining a plurality of entity indicators. The method can include determining a peer group of entities for the entity based on the entity indicators. The method can include obtaining a plurality of loss event records for the peer group. The method can include executing, based on the loss event records, a plurality of Monte Carlo simulations to generate loss simulation data. The method can include identifying, based on the loss simulation data, an expected probability value. The method can include providing a risk factor score indicative of a cyber security risk of the entity based on the identified expected probability value. The method can include providing a cyber resilience rating for the entity based on a combination of the risk factor score, a fortitude factor score, and a governance factor score.

Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.

Abstract: Systems and methods are disclosed for providing a cyber resilience rating. A method can include obtaining a plurality of entity indicators. The method can include determining a peer group of entities for the entity based on the entity indicators. The method can include obtaining a plurality of loss event records for the peer group. The method can include executing, based on the loss event records, a plurality of Monte Carlo simulations to generate loss simulation data. The method can include identifying, based on the loss simulation data, an expected probability value. The method can include providing a risk factor score indicative of a cyber security risk of the entity based on the identified expected probability value. The method can include providing a cyber resilience rating for the entity based on a combination of the risk factor score, a fortitude factor score, and a governance factor score.

Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.

Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

Abstract: In some implementations, a system for removing oxygen from a container includes a recirculation pump and an oxygen removal device. The recirculation pump includes an intake and a discharge, and the intake includes a first connector. The discharge is fluidically connected to an oxygen removal device.

Abstract: Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.

Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.

Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.

Abstract: Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.

Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the f-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.

Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.

Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.